1 / 20

George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics

Workings of the SNM Clinical Trials Network Centralized IND for FLT. George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics. Discussion today includes background information, comments and references to the SNM Clinical Trials Network Centralized IND

Download Presentation

George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Workings of the SNM Clinical Trials Network Centralized IND for FLT George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics

  2. Discussion today includes background information, comments and references to the SNM Clinical Trials Network Centralized IND Selection of [F-18] FLT: an Investigational, non-FDA approved, PET Imaging Agent

  3. FDA / IOM Meeting – October 2007 Therapeutic Drug Developers Comments • PET imaging desired for Multi-center Therapeutic Trials …but ... numerous deficiencies with PET imaging ISSUES • Lack of qualified & experienced imaging centers for large (200+ sites) multi-center Phase 3 clinical trials • Limited supply of known/desired investigational PET agents • No standardized PET imaging acquisition protocols • No harmonized PET imaging report output • Industry could not effectively implement PET imaging in multi-center therapeutic clinical trials

  4. SNM Assessment Efforts Multiple Discussions: • Therapeutic Developers • Participating PET Imaging Centers • FDA: Pre-IND Process Results: • Multiple IND Design Solutions • Regulatory • CMC • Imaging Standardization

  5. Solution Topics • Clinical Trials Network (CTN) Sites Registry • Selection of IND biomarker – [F-18] FLT • Distributed Manufacturing of PET agents – CMC • Imaging Standardization

  6. Topic 1: Clinical Trials Sites Registry • International Registry - Investigators’ Sites • Industry necessity & reality • “Pick list” to match therapeutic sites • Criteria to enable industry review & site selection • Enrollment & qualifications • Location • Equipment – hardware & software • Personnel • Access to investigational imaging agents • Participation: phantom program – clinical trials

  7. International PET imaging sites & PET manufacturers

  8. Areas of Interest • Selection: [F-18] FLT (Oct. 2008) Topic 2: Centralized IND Selection 8

  9. Selection Criteria for [F-18] FLT • Investigational PET imaging biomarker • Literature reports of “potential” for demonstrating tumor proliferation • Potential as a surrogate marker for evaluating investigational oncology therapeutics as well as existing therapeutics • Broadly applicable for lung, breast, esophageal, GI, brain, lymphoma PRE-TX 22 days 113 days

  10. Topic 3: Distributed Manufacturing of PET Agents Distributed Multicenter Manufacturing of PET Imaging • FDA: Anticipates “single GMP product” • PET production • Multicenter methods of production of the investigational PET product • Multiple “similar” PET products by end-product specifications

  11. Using the SNM Centralized IND for [F-18] FLT • FDA must review CMC for all manufacturing sources & methods • CMC from all manufacturers supplying [F-18] FLT to trials must be submitted directly to IND or through letter of cross-reference to a filed DMF • FDA defines acceptable ranges for [F-18] FLT by end-product specifications • FDA accepted [F-18] FLT products = “single IND GMP product”

  12. Drug Master File (DMF) DMF = Efficient CMC submission tool for manufacturers Drug Manufacturer’s Submits Information – Chemistry, Manufacturing and Controls (CMC) of a drug product or a component of a drug product to FDA file room to permit the FDA to review this information upon request only and in support of a specific submission

  13. FDA Regulatory DMF Background Five Types • I: Plant information • II: Drug substance, drug product, intermediates and material used in their manufacture • III: Packaging • IV: Excipients • V: Other clinical, toxicology

  14. Key Point CMC information must be submitted in centralized IND • CMC may be directly submitted in IND submission or • CMC may be submitted through a letter of cross-reference to an existing DMF filed with FDA

  15. Letter of Authorization (LOA) - Enables FDA review of DMF • The DMF Holder (manufacturer) MUST submit an LOA (2 copies) to the DMF and route a separate copy to the IND Applicant • The Applicant submits LOA in their IND submission… the mechanism to enable review of the DMF by FDA • The DMF will be reviewed ONLY when it is referenced in an IND submission • In Europe, the LOA is called a Letter of Access

  16. Topic 4: Imaging Standardization Solutions • Clinical imaging with a standardized protocol • International imaging clinical site registry – hardware/software • Clinical trials educational programs for multicenter trials • Pre-clinical imaging standardization - Phantom Program • Oncology / CNS / Cardiovascular

  17. SNM Imaging Phantom Program [F-18] FLT fillable phantoms • Qualitative & Quantitative (SUV) • VA system • Torso: Oncology • Head/Brain: CNS • Cardiac

  18. Plans for Future Centralized IND • FDG • FLT • FDOPA • FAZA • FMISO • Ga-68 octreotide • FES • FHDT • C-11 acetate

  19. Review: Solution Topics • Clinical Trials Network (CTN) Sites Registry • Selection of IND biomarker – [F-18] FLT • Distributed Manufacturing of PET agents – CMC • Imaging Standardization

  20. Thank You George Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics george.mills@perceptive.com Disclosures: • Consultant to SNM (Society of Nuclear Medicine) • Employee: PAREXEL/Perceptive Informatics - CRO

More Related